Flash FinanceUS
After hours S&P 5007,376.86+0.31% Nasdaq24,579.42+1.09% Dow 3051,285.73-0.46% Russell 20002,754.11+0.89% Nasdaq-10026,989.99+1.35% MidCap 4003,602.50+0.56% SmallCap 6001,673.98+0.05% VIX25.64-9.01% 10Y Yield4.86+0.45% Close of Nov 06, 2026
AI brief of an SEC Form 8-K · Incannex Healthcare Inc. (IXHL)

Incannex Doses First Patient in Phase 2 DReAMzz Study of IHL-42X

Positive Impact 3 of 5 other Written later

Incannex Healthcare announced on August 25, 2026 that the first patient has been dosed in the DReAMzz Phase 2 dose-optimization study of IHL-42X, its oral drug candidate for obstructive sleep apnea. The company says the study is designed to inform dose selection for its planned Phase 3 program. The filing contains no financial results, guidance or funding figures.

Key points

  • First patient dosed in the DReAMzz Phase 2 study, announced August 25, 2026
  • All 14 DReAMzz sites have Institutional Review Board approval, and the study uses 14 clinical trial sites across the United States
  • Builds on prior Phase 2 RePOSA results showing statistically significant AHI reductions versus placebo, with individual reductions of up to 83%, and FDA Fast Track designation for IHL-42X

The filing

CompanyIncannex Healthcare Inc. (IXHL)
Form8-K, current report
Filed with the SECAug 25, 2026, 7:30 AM ET
Accession number0001213900-26-093244

Items reported: 7.01 Regulation FD Disclosure

Read the filing on SEC.gov ↗

Written by AI on Nov 9, 2026, 11:45 AM ET, from this filing only. Written later: this filing was briefed after the fact, when past filings were added to the site, so the brief may be read with hindsight; the filing itself is the record of what was known on August 25, 2026.

Briefs are written by AI from the filing text and can contain mistakes — open the filing before acting on anything. Impact (1-5) and tone are the AI's reading of the filing for shareholders, not a price forecast. Not investment advice.